Loading...
Market
Will PBGENE-HBV trial meet its primary endpoint by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official trial results published by Precision BioSciences or authoritative medical journals
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Yes • 50%
No • 50%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%